Why the study?
Does the CHOP regimen provide durable long-term remission and acceptable functional status in patients with diffuse histiocytic lymphoma?
Does the CHOP regimen provide durable long-term remission and acceptable functional status in patients with diffuse histiocytic lymphoma?
The CHOP regimen provides durable long-term remission in over half of complete responders with diffuse histiocytic lymphoma, though it is associated with an increased risk of sexual dysfunction.
No takes yet. Share an insight, caveat, or question.
Supports durable remissions with CHOP in diffuse histiocytic lymphoma; leaves open net benefit given sexual dysfunction risks.
Armitage et al. (1984) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: